MedTrace Logo

Exploring the Effects of Lactobacillus Paracasei PS23 on Workplace-related Stress Symptoms Among Office Workers

NCT05826704 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-08-15

No results posted yet for this study

Summary

A total of 120 subjects are expected to be recruited over a 3-year period starting after IRB approval, divided into two groups of 60 subjects, receiving PS23 or placebo, and completing a 6-week trial period.

Conditions

  • Stress

Interventions

DIETARY_SUPPLEMENT

Probiotics

Participants will be taking 2 capsule a day for 6 weeks

Sponsors & Collaborators

  • Bened Biomedical Co., Ltd.

    collaborator INDUSTRY

  • Mackay Memorial Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-30
Primary Completion
2023-12-31
Completion
2024-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05826704 on ClinicalTrials.gov